Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17476568 | 0.86 | — | — | |
| SCHEMBL19043523 | 0.83 | TSHR (0.37) | DAO | |
| SCHEMBL98083 | 0.82 | — | — | |
| SCHEMBL12822222 | 0.80 | DAO (0.34) | DAOKDM1AMAOAMAOB | |
| SCHEMBL3167253 | 0.78 | DAO (0.33) | DAOKDM1AMAOAMAOB | |
| SCHEMBL96803 | 0.77 | — | — | |
| SCHEMBL3020365 | 0.77 | — | — | |
| SCHEMBL17732249 | 0.76 | KDM1A (0.38) | DAOKDM1AMAOAMAOB | |
| SCHEMBL23245569 | 0.75 | — | — | |
| SCHEMBL21114288 | 0.75 | ADH1B (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024204554-A1 | SPIROCYCLIC MORPHINAN DERIVATIVE | 日本ケミファ株式会社 | 2024-10-03 | — | — | WO | claimed |
| EP-4735451-A1 | SUBSTITUTED CONDENSED TRICYCLIC AMINE COMPOUNDS AND USES THEREOF AS RAS INHIBITORS | Kumquat Biosciences Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260028358-A1 | SUBSTITUTED HETEROAROMATIC AMINES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12319698-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4543868-A1 | COMPOUNDS AND METHODS FOR DEGRADING CASEIN KINASE 1 ALPHA | Pin Therapeutics, Inc. (KR) | 2025-04-30 | — | — | EP | disclosed |
| CN-119451950-A | Compounds and methods for degrading casein kinase 1 alpha | 匹恩治疗株式会社 | 2025-02-14 | — | — | CN | disclosed |
| WO-2025007000-A1 | SUBSTITUTED CONDENSED TRICYCLIC AMINE COMPOUNDS AND USES THEREOF AS RAS INHIBITORS | KUMQUAT BIOSCIENCES INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024204554-A1 | SPIROCYCLIC MORPHINAN DERIVATIVE | 日本ケミファ株式会社 | 2024-10-03 | — | — | WO | disclosed |
| WO-2024003749-A1 | COMPOUNDS AND METHODS FOR DEGRADING CASEIN KINASE 1 ALPHA | PIN THERAPEUTICS, INC. (KR) | 2024-01-04 | — | — | WO | disclosed |
| CN-116583287-A | Pyridazinone heterocyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20120149660-A1 | NOVEL N-SUBSTITUTED 5-HYDROXYPYROLLINDES AS INHIBITORS OF MDM2-P53 INTERACTIONS | LIU JIN-JUN (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2012076513-A1 | 3-CYANO-1-HYDROXYMETHYL-2-PHENYLPYRROLIDINE DERIVATIVES AS INHIBITORS OF MDM2-P53 INTERACTIONS USEFUL FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
| US-7872028-B2 | Diaminopropanol renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872028-B2 | Diaminopropanol renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872028-B2 | Diaminopropanol renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | VITAE PHARMACEUTICALS, INC. | 2009-07-23 | — | — | US | disclosed |
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | VITAE PHARMACEUTICALS, INC. | 2009-07-23 | — | — | US | disclosed |
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | VITAE PHARMACEUTICALS, INC. | 2009-07-23 | — | — | US | disclosed |
| WO-2007117557-A2 | DIAMINOPROPANOL RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117557-A2 | DIAMINOPROPANOL RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319698-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | DAO 2910/4885KDM1A 1762/4885MAOA 2865/4885 |
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | DNPEP, ACE, DPEP1 | DAO 66/4885KDM1A 1337/4885MAOA 1182/4885 |
| US-20260028358-A1 | SUBSTITUTED HETEROAROMATIC AMINES AND USES THEREOF | HRAS, KRAS, BCL6 | DAO 2741/4885KDM1A 4445/4885MAOA 3514/4885 |
| US-20120149660-A1 | NOVEL N-SUBSTITUTED 5-HYDROXYPYROLLINDES AS INHIBITORS OF MDM2-P53 INTERACTIONS | TP53, MDM2, TP53BP1 | DAO 3967/4885KDM1A 1729/4885MAOA 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.